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Background: New RTS,S malaria vaccines may soon be licensed, yet its cost-effectiveness is unknown. Before the
widespread introduction of RTS,S vaccines, cost-effectiveness studies are needed to help inform governments in
resource-poor settings about how best to prioritize between the new vaccine and existing malaria interventions.
Methods: A Markov model simulated malaria progression in a hypothetical Malawian birth cohort. Parameters were
based on published data. Three strategies were compared: no intervention, vaccination at one year, and long-lasting,
insecticide-treated nets (LLINs) at birth. Both health service and societal perspectives were explored. Health outcomes were
measured in disability-adjusted life years (DALYs) averted and costed in 2012 US$. Incremental cost-effectiveness ratios
(ICERs) were calculated and extensive sensitivity analyses were conducted. Three times GDP per capita ($1,095) per DALY
averted was used for a cost-effectiveness threshold, whilst one times GDP ($365) was considered ‘very cost-effective’.
Results: From a societal perspective the vaccine strategy was dominant. It averted 0.11 more DALYs than LLINs and 0.372
more DALYs than the no intervention strategy per person, while costing $10.04 less than LLINs and $59.74 less than no
intervention. From a health service perspective the vaccine’s ICER was $145.03 per DALY averted, and thus can be
considered very cost-effective. The results were robust to changes in all variables except the vaccine and LLINs’ duration
of efficacy. Vaccines remained cost-effective even at the lowest assumed efficacy levels of 49.6% (mild malaria) and 14.2%
(severe malaria), and the highest price of $15. However, from a societal perspective, if the vaccine duration efficacy was set
below 2.69 years or the LLIN duration of efficacy was greater than 4.24 years then LLINs became the more cost-effective
strategy.
Conclusion: The results showed that vaccinating Malawian children with RTS,S vaccines was very cost-effective from both
a societal and a health service perspective. This result was robust to changes in most variables, including vaccine price
and vaccine efficacy, but was sensitive to the duration of efficacy of the vaccine and LLINs. Given the best evidence
currently available, vaccines can be considered as a very cost-effective component of Malawi’s future malaria control
programmes. However, long-term follow-up studies on both interventions are needed.
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Malaria is one of the leading causes of morbidity and
mortality in Africa [1]. Malawi’s 14.9 million people
live in a hyperendemic malarial area with stable and high
malaria transmission rates, predominantly caused by
Plasmodium falciparum [2,3]. Malawians suffered 6.1* Correspondence: seokelly@gmail.com
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unless otherwise stated.million cases of malaria in 2009, accounting for 30% of
outpatient appointments and costing $2.7million [4].
National malaria control programmes include a selection
of measures such as environmental measures, improved
case management, intermittent preventative treatment,
indoor residual spraying, and insecticide-treated nets
(ITNs). ITNs have been established as one of the most
cost-effective interventions for controlling malaria, costing
$4-10 per disability-adjusted life year (DALY) averted [5].
Long-lasting, insecticidal nets (LLINs) have replaced ITNs. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Structure of the model. Every five days, cohort members
face the probability of moving to the next health state as depicted
by arrows in the diagram.
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to increase the coverage of LLINs up to 80% by 2015 [6,7].
Although no malaria vaccine is currently licensed, the
RTS,S vaccine against P. falciparum is considered to be
the most promising. A phase III trial of the RTS,S vaccine
is underway, and early results show comparable efficacy to
LLINs [8-15].
Given the limited budget for health expenditures in
Malawi, it may not be immediately affordable to add
vaccination to Malawi’s current malaria control plan. As
such, it is vital that the government and donors are able
to determine which interventions to prioritize in their
malaria control programme. Therefore, determining the
cost-effectiveness of implementing a new vaccination
programme in comparison to Malawi’s proposed wide-
spread provision of LLINs is a key concern, as this will
enable prioritization of scarce resources [16]. Existing re-
search has not addressed this question adequately. The
cost-effectiveness of a malaria vaccine in Tanzania has
recently been estimated at between $12 and $190 per
DALY averted, depending on the vaccine price [17,18].
This result provides limited insight however, since it did
not compare vaccines directly to a best-alternative op-
tion, such as LLINs. Currently, only one study has dir-
ectly compared the cost-effectiveness of vaccines and
ITNs, but this was carried out in 1998, prior to the de-
velopment of LLINs and the latest RTS,S trials [19].
Thus, the cost-effectiveness of the new vaccine has not
yet been examined rigorously.
Furthermore, since the RTS,S vaccines are likely to be
licensed in a couple of years, an early evaluation would
help reduce any unnecessary lead time between product
regulatory approval and its utilization [20]. Hence, this
study examines the cost-effectiveness of a strategy to de-
liver RTS,S vaccines to one-year old children in Malawi
compared with a strategy to provide LLINs to newborns




A Markov model was constructed using the TreeAge
Pro 2009 software and was used to compare three strat-
egies for controlling malaria in Malawi: vaccines, LLINs
and no intervention. A static model was chosen because
herd immunity would be unachievable with the current
scenario of vaccinating infants only, since adults would
continue to be a large parasite reservoir [21,22].
The population in the model was a hypothetical Malawian
birth cohort. The cohort experienced two epidemiological
processes. Firstly, the age-specific non-malaria mortality rate
was applied, based on World Health Organization (WHO)
life tables [23]. Secondly, malaria morbidity and mortality
was modelled using five mutually exclusive health states –well, mild malaria, cerebral malaria (CM), severe malarial
anaemia (SMA), and death (Figure 1) [24]. Cycle lengths
were set at five days because one cycle approximates the
average mild disease episode, and two cycles approximates
the average duration of mild malaria and progression to se-
vere malaria (CM or SMA) [24]. Age-specific, annual epi-
demiological rates of each disease state were therefore
transformed into five-day probabilities [25].
Perspective
Health services and societal perspectives were employed
for the data collection and the analysis. Its results were
then reported separately.
Transition probabilities
Comparator: providing no intervention
The transition probabilities for the no intervention strategy
were derived from epidemiological data collected prior to
the widespread provision of ITNs or LLINs. The best avail-
able estimates come from two meta-analyses of active case-
finding studies in sub-Saharan Africa countries with similar
climates [24,26]. For the LLIN strategy and the vaccine
strategy, these transition probabilities were adjusted by the
efficacy of the intervention and the proportion of the popu-
lation successfully protected. All probabilities used in this
model are given in the Table 1 and the detailed transition
matrices can be seen in Additional file 1.
Comparator: delivering LLINs to children
The LLIN strategy modelled the delivery of one LLIN
for every two children through existing channels (ante-
natal clinics and at birth), reaching a coverage rate of
Table 1 Base-case values and ranges used in sensitivity analysis
Description Value Reference






Public health systems 0.51 0.26 0.77 [27] (±50%)
Households 0.50 0.21 1.00 [28] (±50%)
Severe malaria (CM, SMA)
Public health systems 12.76 6.38 19.14 [27] (±50%)




Adults 2.52 1.26 3.78 [16,27] (±50%)
Children 1.11 0.56 1.67 [16,27] (±50%)
Death 4.76 2.38 7.14 [16] (±50%)
Vaccine costs
Price per dose 7 1 15 [29,30] (Min, Max)
Administration per dose 0.37 0.19 0.57 [30] (±50%)
Total costs for 3 doses 22.11 3.57 46.71
LLINs costs
LLIN per two persons 3.16 2.23 5.23 [31,32] (Min, Max)
DALY-related parameters
Life expectancy 47.1 years [23]
Disability weights [33]
Mild malaria 0.191 0.172 0.211
CM 0.471 0.443 0.471




Mild Malaria 0.539 0.496 0.578 [12] (95% CI)
Severe Malaria (CM, SMA) 0.313 0.142 0.448 [12] (95% CI)
Death 0.2 0.15 0.25 [19] (±25%)
Duration of protection 45 months 11 months 10 years [14]
Vaccine coverage 0.85 0.64 0.99 [34,35] (Min, Max)
LLIN protection efficacy
Mild Malaria 0.5 0.43 0.62 [36] (Min, Max)
Severe Malaria (CM, SMA) 0.45 0.2 0.63 [36] (95% CI)
Death 0.17 0.1 0.24 [36] (95% CI)
Duration of protection 3 years 3 years 5 years [37] (Min, Max)
LLIN coverage 80% 55.4% 80% [7] (Baseline (2010) - Target (2015))
LLIN use 88% 87% 90% [38] (95% CI)
Discount rate% 3% 0% 6% [39]
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were chosen as a comparator intervention because they
are highly cost-effective and because they form such a
large part of the government’s malaria control strategy
[6,7]. An 88% correct usage rate for LLINs was taken
from a large Malawian survey in 2009 [38]. A Cochrane
meta-analysis found that LLINs had a protective efficacy
of 50% against mild cases, 45% against severe and 17%
against death, and last up to three years, according to
WHO data [36,37].
Intervention: vaccinating children with RTS,S vaccines
The vaccine strategy represents the delivery of three
doses of the RTS,S vaccine to infants as per the current
phase III trial [40]. The model included infants who
were to be vaccinated through the Expanded Programme
on Immunization (EPI) and receive their last dose at age
one. Therefore, for the effectiveness of the vaccine, data
from the ongoing phase III trials in African children
were used, which showed a protective efficacy of 53.9%
against mild cases and 31.3% against severe cases if
given to children aged five to 17 months [12,15]. Severe
malaria includes CM and SMA. However, the clinical tri-
als were not designed to study impact on mortality rates,
and so an estimate of 20% from a previous modelling
study was used [19].
New vaccines tend to achieve a lower coverage rate
than long-standing vaccines. Given that Malawi’s cover-
age rate in 2011 was greater than 85% for all of its eight
EPI vaccines, the coverage of the RTS,S vaccine was con-
servatively assumed to be 85% [34]. Since follow-up data
from the phase III vaccine study are only available for
the first year, the duration of vaccine efficacy is not
known. Previously however, the RTS,S/AS02 vaccine
retained its efficacy for 45 months in trials, therefore this
was taken as the most likely duration of vaccine efficacy
[14]. No booster doses were assumed in the model after
this duration because the efficacy of a booster dose is
not currently known.
Health outcomes (DALYs)
DALYs averted were the primary health outcome of
interest in this analysis, calculated using Malawian life
expectancy [23,41]. Disability weights were assigned ac-
cording to the global burden of disease (0.21 for mild
malaria, 0.47 for CM) [33]. SMA does not have an offi-
cial value so CM’s value was used and this assumption
was tested in the sensitivity analyses. DALYs were calcu-
lated without age-weighting and with a 3% discount rate,
as this has become standard practice [42].
Costs
Costs were collected from both a health services per-
spective and from a societal perspective. All costs werecollected from published literature (Table 1). All costs
were inflated to 2012 US dollars, and discounted at 3%
per year [43,44]. For costs of treatment by the healthcare
provider, the data on Malawi’s average recurrent cost per
malaria episode were used [27].
Vaccine costs are composed of vaccine price and ad-
ministration costs. The vaccine price was derived from
existing EPI vaccines of developing countries since no
price for the malaria vaccine exists. Especially, among all
EPI vaccines, the recent vaccines’ introductory prices
were employed as reference prices [29,30]. Therefore,
the vaccine price was varied from $1 to $15 per dose,
using $7 as the base case. The recurrent administration
cost of the Malawian diphtheria, tetanus, pertussis
(DTP) vaccine ($0.37 per dose) was used for administra-
tion costs of RTS,S vaccines [30]. No need for significant
new capital investments were assumed because infants
will be vaccinated through existing EPI facilities, which
already achieve over 85% vaccination coverage [34].
For LLIN costs, it used a detailed assessment of a
Malawian ITN programme to estimate the average ad-
ministration cost per ITN delivered and then added
LLINs costs ($4.50) [31,32]. One LLIN is provided for
every two children so the final cost was halved.
For the societal perspective, the model included the
additional costs incurred by patients and carers due
to illness. For patients’ out-of-pocket payments, it used
data from a large 2009-10 Malawian household survey
[28]. Then the human capital approach was adopted to
estimate productivity losses due to illness. Wages lost
due to adult illness and carers’ wages lost due to child-
hood malaria were calculated, using GDP per capita of
Malawi and survey data on time lost due to malaria in
Malawi [16,27]. Similarly, the lost productivity due to
death in working-age (14-65) people was estimated from
GDP per capita.
Cost-effectiveness threshold (CET)
Interventions that are both cheaper and more effective
than the alternatives are clearly the most cost-effective
option and are said to be ‘dominant’. Interventions that
are more expensive and more effective were only recom-
mended as cost-effective if their incremental cost-effect-
iveness ratio (ICER) was below Malawi’s cost-effectiveness
threshold (CET). It used the thresholds established by the
2003 World Health Report, which considered interven-
tions with an incremental cost per DALY averted of less
than three times a country’s GDP per capita ($1,095) ‘cost-
effective’ and less than one times GDP ($365) as ‘very
cost-effective’ [39].
Sensitivity analysis
One-way sensitivity analyses were performed on all vari-
ables to assess their impact on the cost-effectiveness
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and lower limits used for each variable. If changes in the
variable resulted in a change in the cost-effectiveness re-
sult, then a threshold analysis was carried out. Further
analysis was carried out on vaccine price, efficacy and dur-
ation of efficacy because these parameters are particularly
uncertain and a better understanding of how much they
impact on the vaccine’s cost-effectiveness will inform fu-
ture vaccine research and guide how the vaccine is incor-
porated into future malaria control programmes.
Results
Cost-effectiveness
In the baseline analysis (Table 2), the vaccine’s ICER
shows that vaccinating infants with the RTS,S vaccine is
very cost-effective for Malawi. When a societal perspec-
tive was taken, the vaccine strategy was the cheapest and
the most effective intervention, dominating the other
two strategies. Per person, it averted 0.11 more DALYs
than LLINs and 0.372 more DALYs than the no inter-
vention strategy, whilst costing $10.04 less than LLINs
and $59.74 less than no intervention. When a health ser-
vices perspective was taken, the vaccine’s ICER was
$145.03 per DALY averted. This ICER is far below the
CET of Malawi ($1,095). Because it is also below the GDP
of Malawi ($365), according to WHO-CHOICE, this ICER
can therefore be considered very cost-effective [39].
Sensitivity analysis
Tornado diagram
One-way sensitivity analyses were performed to determine
the impact of each variable on the model, whilst holding
all other variables at their baseline values. These are
depicted in tornado diagrams in Additional files 2 and 3.
The net benefit produced by each strategy was sensitive to
changes in discount rates, productivity losses, vaccine effi-
cacy duration, vaccine coverage, vaccine efficacy, vaccine
price, and LLINs efficacy duration. However, only the
LLIN duration of efficacy, the vaccine duration of efficacy
and the vaccine coverage rate had any impact on the cost-
effectiveness result. To explore this further a threshold
analysis was carried out on these three variables.Table 2 Base-case scenario cost-effectiveness result from a he
Perspective Societal perspective






Incremental cost/DALY averted (ICER) (Dominated)Threshold analysis
The baseline analysis assumed that the RTS,S vaccine
would be efficacious for 3.75 years and showed that it
is cost-effective compared with LLINs. However, the
threshold analysis from the societal perspective showed
that vaccines were very cost-effective (i e, had an ICER
under $365) only if the duration of vaccine efficacy was
over 2.84 years (see Table 3). They were cost-effective
(i e, had an ICER under $1,095) only if their duration
was above 2.69 years. In other words, if vaccine dur-
ation fell below 2.69 years, LLINs appeared to be more
cost-effective than vaccination. A similar result was ob-
served from the health service perspective (Table 3).
Likewise, three years was assumed to be the duration
of LLINs’ efficacy in the baseline analysis. However, the
threshold analysis from a societal perspective showed
that vaccines were very cost-effective (i e, had an ICER
under $365) only if the duration of LLIN efficacy was
under 4.07 years (Table 4). They were cost-effective (i e,
had an ICER under $1,090) only if their duration was
under 4.24 years. In other words, if LLINs were effective
longer than 4.24 years, vaccines appeared to be cost-
ineffective compared to LLINs. A similar result was seen
from the health service perspective (Table 4).
The baseline analysis assumed that the vaccine would
cover 85% of the population. From a health service per-
spective, varying this from 64 to 99% did not affect the
cost-effectiveness result. From a societal perspective the
vaccine was always cost-effective (i e, ICER under $1,095),
however the vaccine coverage rate had to be over 67.62%
to be very cost-effective (i e, ICER under $365).
Uncertainty in the vaccine price
Further analysis was carried out on the impact of
changes of vaccine price to ICER because RTS,S vaccine
price is basically unknown and is of critical interest to
all stakeholders including multilateral donor agencies.
Results are presented in the Table 5 and suggest that the
vaccine strategy is very cost-effective through a range of
prices.
From a societal perspective, both the LLINs and the no
intervention strategies were dominated by the vaccinealth services’ and a societal perspective
Health services perspective
No intervention No intervention LLIN Vaccine
$1,208.51 $7.69 $8.67 $24.68
$59.73 $0.97 $16.01
4.613 4.613 4.351 4.241
-0.372 0.262 0.11
$262.00 $1.67 $1.99 $5.82
(Dominated) $3.72 $145.03
Table 3 Threshold analysis results on the duration of
vaccine efficacy
Perspective Societal Health services
Vaccine duration above which vaccines
become cost-effective (CET = $1,090)
2.69 years 2.73 years
Vaccine duration above which vaccines
become very cost-effective (CET = $365)
2.84 years 3.05 years
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ever, the no intervention strategy was always dominated
regardless of the vaccine price. The vaccine’s ICER at the
top price of $15 per dose was $93.84 per DALY averted
which can be considered very cost-effective for Malawi
(i e, under $365 per DALY averted). From a health services
perspective, the vaccine’s ICER gradually increased as the
vaccine price was inflated, reaching $329.78 per DALY
averted at the top price of $15 per dose, thus remaining
very cost-effective for Malawi.
Methodological uncertainty in the time horizon and
discount rates
The model results remained consistent even when time
horizons were varied from 20 to 60 years (see Additional
file 4). Whilst the vaccine’s ICER was sensitive to
changes in discount rates, the overall cost-effectiveness
result did not change (see Additional file 5). From a so-
cietal perspective, the vaccine strategy was dominant
over the other two options when discount rates up to
5% were applied. However, when 6% discount rate was
used, vaccination was no longer dominant and an ICER
of $50.53 per DALY averted was seen. From a health ser-
vices’ perspective, the ICER of the vaccine strategy was
$73.69 per DALY averted with a 0% discount rate, and
$255.01 per DALY averted with a 6% discount rate. In
other words, the RTS,S vaccine was found to be cost-
effective regardless of changes in time horizons and dis-
count rates.
Two-way sensitivity analysis on the duration of vaccine
efficacy and price
Two-way sensitivity analyses were carried out on the
duration of vaccine efficacy and the vaccine price. As
shown in Figures 2 and 3, vaccine price has little impact
on which intervention the model finds to be the most
cost-effective, however the impact of the duration of
vaccine efficacy appears to be significant. This is in lineTable 4 Threshold analysis results on the duration of
LLIN efficacy
Perspective Societal Health services
LLIN duration below which vaccines
become cost-effective (CET = $1090)
4.24 years 4.18 years
LLIN duration below which vaccines
become very cost-effective (CET = $365)
4.07 years 3.80 yearswith the threshold analysis results. In other words, the
cost-effectiveness of RTS,S vaccines might be greatly de-
termined by their duration of protection, but not by
their price.
Two-way sensitivity analysis on the vaccine efficacy and
vaccine price
Even at the lowest assumed vaccine efficacy level and the
highest price of $15 per dose, the two-way sensitivity ana-
lysis revealed that the vaccine strategy remained the most
cost-effective intervention for Malawi. The vaccine’s ICER
was $614.62 per DALY averted from the health service
perspective and $351.38 from the societal perspective.
Discussion
The cost-effectiveness of an RTS,S malaria vaccination
strategy was compared with two alternative strategies
(no intervention and the provision of LLINs), using a
Markov model. From a health services’ perspective, the
vaccine’s base-case ICER was $145.03 per DALY averted,
and this was less than Malawi’s very cost-effective
threshold of US$365. From a societal perspective, the
vaccine strategy was dominant (i e, it was cheaper and
more effective than the two alternative strategies). Thus,
this analysis showed that, compared to LLINs, delivering
the RTS, S vaccine to one-year old children is very cost-
effective for Malawi.
This is the first study to directly compare the cost-
effectiveness of the RTS,S vaccine with LLINs. Previous
cost-effectiveness studies on the malaria vaccine support
the finding that vaccination is cost-effective compared
with respective comparator interventions. In 2006, Tediosi
and colleagues compared a combined programme of vac-
cination plus malaria case management with only malaria
case management in Tanzania from a societal perspective
[17]. They evaluated the cost-effectiveness of vaccination
depending on different vaccine price scenarios. When the
lowest price of $1 per dose was assumed, the ICER was $8
per DALY averted. When the highest price range was as-
sumed ($20 per dose), the vaccine’s ICER was $140 per
DALY averted. It is in line with the findings from a societal
perspective that the vaccine strategy dominated LLINs at
the price of $1 per dose and produced an ICER of $93.84
per DALY averted when the highest vaccine price was as-
sumed to be $15 per dose.
Further support for the results of this study comes
from a recent modelling paper on different malaria vac-
cine types, undertaken from a health services’ perspec-
tive, showed that the vaccine’s ICER was $160 per DALY
averted at a price of $10 per dose [18]. This is similar to
the findings from a health services’ perspective that the
vaccine’s ICER was $52.65 at a price of $3 per dose and
$329.78 at $15 a dose. These previous findings are not
perfectly comparable to this study because they lack a
Table 5 Changes in the vaccine’s ICER according to different vaccine price scenarios
Vaccine price
per dose
Societal perspective Health services’ perspective
Strategy ranking Incremental cost/DALY
averted (ICER)




LLINs (Dominated) LLINs $3.72
No intervention (Dominated) Vaccines $6.46
$3
Vaccines No intervention
LLINs (Dominated) LLINs $3.72
No intervention (Dominated) Vaccines $52.65
$5
Vaccines No intervention
LLINs (Dominated) LLINs $3.72
No intervention (Dominated) Vaccines $98.84
$7
Vaccines No intervention
LLINs (Dominated) LLINs $3.72
No intervention (Dominated) Vaccines $145.03
$9
Vaccines No intervention
LLINs (Dominated) LLINs $3.72
No intervention (Dominated) Vaccines $192.22
$11
LLINs No intervention
Vaccines $1.46 LLINs $3.72
No intervention (Dominated) Vaccines $237.41
$13
LLINs No intervention
Vaccines $47.65 LLINs $3.72
No intervention (Dominated) Vaccines $283.60
$15
LLINs No intervention
Vaccines $93.84 LLINs $3.72
No intervention (Dominated) Vaccines $329.78
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theless, they support the conclusion that the RTS,S vac-
cines are cost-effective over a wide range of different
vaccine price scenarios.
Graves’ study [19] appears to be the most comparable
study to the analysis of this study since he used ITNs as a
comparator. It found that vaccination was cheaper and
less effective than ITNs. This result is likely to be because
the study was carried out before the development of the
more efficacious RTS,S/AS01 vaccines. Furthermore, the
study is unable to inform about the vaccine’s relative cost-
effectiveness since ICERs were not calculated.
The result of this study was robust to changes in most
variables. The RTS,S vaccine price is highly uncertain,
and its efficacy has only been established in one trial.
Therefore it is reassuring that the two-way sensitivity
analysis found that even when the lowest vaccine effi-
cacy value and the highest vaccine price were combined,
the vaccine strategy was still very cost-effective. This is
similar to previous findings that a malaria vaccine with
50% efficacy would be highly cost-effective [45].If new malaria vaccines were protective for a lifetime
with high efficacy, policy-makers’ decision making would
be easier. The reality is, however, that any malaria vac-
cine seems unlikely to be highly efficacious in the near
future [46]. Indeed, RTS,S vaccines are considered ‘leaky’,
which means they may not protect individuals consist-
ently from infection. Furthermore, Bejon et al. pooled
vaccine efficacy data from phase II trials of 11 sites in
Africa and analysed the variation in vaccine efficacy [47].
Their findings reported that vaccine efficacy is signifi-
cantly varied by the duration of protection. For example,
its efficacy declined to 0% at the three-year time of vac-
cination from 36% at the time of vaccination.
Likewise, this study result was particularly sensitive to
the duration of vaccine efficacy and the duration of
LLIN efficacy. The findings show that, in order to be
cost-effective for Malawi, RTS,S vaccines must remain
efficacious for longer than 2.69 years from a societal per-
spective (2.73 years from the health service perspective).
This is in line with Engers and Godal’s analysis that the
vaccine would need to provide three years of immunity
Figure 2 Two-way sensitivity analysis of vaccine price and efficacy duration: health services’ perspective. This graph demonstrates the
range of vaccine prices and vaccine duration of efficacy where vaccines are more cost-effective than LLINs.
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of efficacy was set at greater than 4.24 years (from a soci-
etal perspective, 4.18 years from a health service perspec-
tive), then LLINs became the more cost-effective strategy.
Thus, long-term follow-up studies of the vaccine’s phaseFigure 3 Two-way sensitivity analysis of vaccine price and efficacy du
vaccine prices and vaccine duration of efficacy where vaccines are more coIII trial are recommended in order to produce more pre-
cise estimates of the vaccine’s efficacy and duration of pro-
tection, and therefore cost-effectiveness.
There are, however, several limitations in this study.
First, although a static Markov model was justified dueration: societal perspective. This graph demonstrates the range of
st-effective than LLINs.
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study, a dynamic model might provide more information
by capturing all indirect effects. However, if herd immun-
ity is included, the cost-effectiveness through added bene-
fits accrued on non-vaccinated people would be improved.
This study therefore assumed a conservative stance and
did not include the potential of herd immunity in this
study. Second, a Markov model assumes the same transi-
tion probability for all participants irrespective of their
previous health state, i e, it is memory-less [49]. Third,
data sources of this study were all secondary and mostly
lacked distributional information. Therefore, to avoid
making excessive assumptions about data, probabilistic
sensitivity analyses were not performed. Fourth, the model
does not allow for any heterogeneity in the population.
However, this is not a major concern in Malawi, which has
high and consistent malarial transmission throughout the
country [50]. Further studies in more heterogeneous
countries may need to model geographical differences.
Fifth, whilst this study modelled all malaria mortality and
the vast majority of malarial morbidity, other malarial dis-
ease states, such as respiratory distress, were not explicitly
modelled. However, this will not influence the result of the
study significantly, since the vast majority of the DALYs
accrued are due to mortality rather than morbidity. Sixth,
in practice most governments in the future are likely to
adopt a blend of interventions in their malaria control
programmes, including both vaccines and LLINs, whereas
this study modelled a strategy of vaccination against
LLINs alone. It is because comparing the two interven-
tions head-to-head enables governments and donors to
prioritize scarce resources towards the more cost-effective
components of a malaria control programme. Lastly, as
more data from RTS,S vaccine phase III trials become
available, more precise vaccine estimates, including the
duration of vaccine efficacy and the efficacy of booster
dose, the efficacy against malaria mortality should become
known. This will enable the cost-effectiveness of RTS,S
vaccines to be evaluated more precisely.
Conclusion
This study found that a malaria vaccine strategy was very
cost-effective for Malawi. From a health service perspective,
although it was more expensive, it was more effective than
LLINs or no intervention, and its ICER was far below the
CET for Malawi. From a societal perspective it was cheaper
and more effective, dominating the other two options. Al-
though the vaccine strategy’s ICER was sensitive to a number
of assumptions, including vaccine price, vaccine efficacy, dur-
ation of vaccine efficacy, discount rates for both outcomes
and cost, the vaccine remained consistently ‘very cost-
effective’ for Malawi. Therefore, the findings of this study
should encourage the Malawian government to incorporate
the vaccine into its control programme once it is licensed.Although this study found vaccines to be more cost-
effective than LLINs, in reality all malaria control pro-
grammes would be a blend of several interventions.
Further studies are thus needed to explore the interaction
between interventions. This will help guide decision
makers on how best to incorporate the vaccine as part
of an optimal package of interventions. Finally, further
studies into the duration of efficacy of the vaccines would
improve the understanding of their cost-effectiveness,
which would be beneficial for policy makers.
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